2026-08-25T14:09:12Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/178372024-02-10T20:01:03Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
García-Aranda, Marilina
author
Redondo, Maximino
2024-02-10T20:01:03Z
2024-02-10T20:01:03Z
2019-03-27
10.3390/cancers11040433
2072-6694
Cancers
http://hdl.handle.net/10668/13778
30934752
http://hdl.handle.net/20.500.12105/17837
Colorectal cancer is the third most common malignancy in men and the second most common cancer in women. Despite the success of screening programs and the development of adjuvant therapies, the global burden of colorectal cancer is expected to increase by 60% to more than 2.2 million new cases and 1.1 million deaths by 2030. In recent years, a great effort has been made to demonstrate the utility of protein kinase inhibitors for cancer treatment. Considering this heterogeneous disease is defined by mutations that activate different Receptor Tyrosine Kinases (RTKs) and affect downstream components of RTK-activated transduction pathways, in this review we analyze the potential utility of different kinase inhibitors for colorectal cancer treatment.
eng
Cancer
Colorectal
Kinases
Receptor
Target
Targeting Receptor Kinases in Colorectal Cancer.
research article